Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

The prognosis of patients with advanced head and neck cancer remain dismal. For this
tumor type, elevated levels of EGFR are associated with a shorter disease free survival and …

Squamous cell carcinoma is responsible for 90% of the head and neck cancers affecting
over 600,000 people worldwide. Radiation therapy, surgery and chemotherapy are the most …

Background Quality of life (QOL) outcomes become critical for survivors of head and neck
cancer. Most QOL studies were based on< 5‐year outcomes and very few addressed> 5 …

Purpose: We evaluated X-ray repair complementing defective repair in Chinese hamster
cells 1 (XRCC1) protein in head and neck squamous cell carcinoma (HNSCC) patients in …

Head and neck squamous cell carcinoma (HNSCC) is a malignancy with an increasing
incidence. To aid with the selection of the most appropriate therapy, biomarkers have …

OBJECTIVES: SIRT1, class III histone deacetylase, has been described to be up-regulated
in various malignancies. However, the opposite results have been reported in other …

Background Growth differentiation factor 15 (GDF 15) is involved in tumor pathogenesis of
oral squamous cell carcinoma (OSCC). The aim of this study was an investigation of the …

Conclusions: We determined that 55% of the patients with oropharynx squamous cell
carcinoma (OPSCC) had human papilloma virus (HPV)-positive tumors. We demonstrated …

PURPOSE: Neuroblastoma is the most common extracranial solid tumor of childhood, and
metastatic disease occurs in a majority of patients. Although radiotherapy (RT) plays an …